Myrexis, Inc. is a development‐stage biopharmaceutical company committed to the discovery, development and commercialization of novel oncology therapeutics. Headquartered in Bothell, Washington, the company leverages a blend of small‐molecule chemistry and RNA‐based technologies to target critical pathways that drive tumor growth and resistance. Myrexis focuses its efforts on solid tumors where there remains significant unmet medical need, with an emphasis on precision medicine approaches that match therapeutic candidates to defined patient populations.
Founded in 1998 as OncoGenex Pharmaceuticals, the company adopted the Myrexis name in early 2014 to reflect a broadened research platform and pipeline. Under its former banner, Myrexis advanced its lead antisense agent through multiple clinical trials, generating insights into biomarker‐driven development. Following pivotal studies, the organization realigned its strategy around next‐generation compounds that address apoptosis regulation, autophagy modulation and kinase‐driven signaling in cancer cells.
Myrexis maintains a pipeline of preclinical and early‐stage product candidates, including small‐molecule inhibitors and novel conjugates designed to enhance tumor selectivity and therapeutic index. The company partners with academic research centers, contract research organizations and international collaborators to conduct translational research and multi‐region clinical trials spanning North America, Europe and Asia. This global footprint supports patient recruitment, biomarker validation and regulatory engagement across key markets.
The company’s management team comprises industry veterans with extensive experience in oncology drug development, clinical operations and regulatory affairs. A board of directors made up of seasoned pharmaceutical and biotech executives provides corporate governance and strategic oversight. Myrexis continues to pursue strategic alliances and licensing opportunities aimed at accelerating its oncology pipeline toward late‐stage clinical evaluation and eventual commercialization.
AI Generated. May Contain Errors.
Free MYRX Stock Alerts